GenFleet Therapeutics (HKG: 2595) announced that its oral KRAS G12D (ON/OFF) inhibitor, GFH375, has been granted its third Breakthrough Therapy Designation (BTD) by China’s National Medical Products Administration (NMPA) – this time for GFH375 in combination with cetuximab (an anti‑EGFR monoclonal antibody) for the treatment of patients with KRAS G12D‑mutated metastatic colorectal cancer (CRC) who have failed prior chemotherapy (oxaliplatin‑, fluoropyrimidine‑, and irinotecan‑based regimens).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Designation | Breakthrough Therapy Designation (third for GFH375) |
| Product | GFH375 (oral KRAS G12D ON/OFF inhibitor) |
| Regimen | GFH375 + cetuximab (anti‑EGFR mAb) |
| Indication | KRAS G12D‑mutated metastatic colorectal cancer after failure of oxaliplatin‑, fluoropyrimidine‑, and irinotecan‑based chemotherapy |
| Designation Date | 30 Sep 2026 |
Drug Profile & Mechanism of Action
- Molecule: Oral KRAS G12D (ON/OFF) inhibitor, independently developed by GenFleet Therapeutics.
- Binding Mode: Non‑covalently binds to the KRAS G12D protein, inhibiting its interaction with downstream effector proteins.
- Mechanism: Disrupts the continuous activation of downstream signaling pathways driven by KRAS G12D in cells, ultimately leading to potent inhibition of tumor cell proliferation.
- ON/OFF Profile: Targets both active (ON) and inactive (OFF) states of the mutant KRAS G12D protein – a design aimed at durable suppression of oncogenic signaling.
- BTD Track Record: Previously became the first oral KRAS G12D inhibitor in China to receive BTD for pretreated non‑small cell lung cancer (NSCLC) and pancreatic cancer.
Development Status
| Program | Setting | Status |
|---|---|---|
| GFH375 monotherapy – pancreatic cancer | Pretreated | Registration Phase III underway |
| GFH375 monotherapy – NSCLC | Pretreated | Registration Phase III underway |
| GFH375 + cetuximab – metastatic CRC | KRAS G12D‑mutated, post‑chemotherapy | BTD granted; clinical development |
Clinical trial data underlying the designation were not disclosed in this announcement.
Market Impact & Outlook
- Third Tumor Type, Third BTD: With designations now spanning NSCLC, pancreatic cancer, and colorectal cancer, GFH375 is establishing itself as one of China’s most broadly recognized assets in the historically undruggable KRAS G12D space.
- High Unmet Need: KRAS G12D is among the most prevalent KRAS mutations in CRC and pancreatic cancer, and patients who progress on standard oxaliplatin‑, fluoropyrimidine‑, and irinotecan‑based chemotherapy have limited effective options – positioning GFH375 combinations as a potential new standard.
- Combination Strategy: Pairing a KRAS G12D inhibitor with cetuximab reflects a mechanistic rationale – blocking EGFR‑driven feedback reactivation – that has become a leading development approach in KRAS‑mutant CRC.
- Registration Momentum: Ongoing registration Phase III studies in pretreated pancreatic cancer and NSCLC set up potential near‑term filing catalysts, while the NMPA’s BTD grants typically accelerate development and review pathways.
- Competitive Edge: As the first oral KRAS G12D inhibitor in China to receive BTD, GFH375 holds first‑mover positioning in the domestic market for this mutation‑defined patient population.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding GFH375, including ongoing registration Phase III studies, the development of the GFH375 plus cetuximab combination, and regulatory expectations under Breakthrough Therapy Designation. Actual results may differ due to risks including clinical trial outcomes, regulatory review timelines, and competitive dynamics.-Fineline Info & Tech
